Tech Company Financing Transactions
Infex Therapeutics Funding Round
On 5/12/2026, Infex Therapeutics received $5.8 million in investment from private investors and Catapult Ventures.
Transaction Overview
Company Name
Announced On
5/12/2026
Transaction Type
Venture Equity
Amount
$5,800,000
Round
Undisclosed
Investors
private investors (Lead Investor) (Jon Moulton)
Proceeds Purpose
The company intends to use the funds to advance its clinical pipeline, specifically preparing for further development of RESP-X after its Phase IIa trial, expanding the MET-X resistance bypass program, and progressing preclinical studies on BamA inhibitors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Mereside, Alderley Park
Alderley Edge, SK10 4TG
UK
Alderley Edge, SK10 4TG
UK
Phone
Website
Email Address
Overview
Infex Therapeutics (also known as InfexTx) acquires, develops, and licenses innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jon Moulton
Chief Executive Officer
Peter Jackson
Browse more venture capital transactions:
Prev: 5/12/2026: Rely venture capital transaction
Next: 5/12/2026: Rogue Snacks venture capital transaction
Share this article
About Our VC Transactions Data
We report on funding rounds that are announced publicly. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs